Sec62/Ki67 dual staining in cervical cytology specimens: a new marker for high-grade dysplasia
- 69 Downloads
In the previous studies, we demonstrated that Sec62 is essential for tumor cell migration, epithelial-to-mesenchymal transition, and intracellular stress tolerance. An increase in Sec62 expression correlated with an increase in cervical dysplasia severity in liquid-based cytology specimens. Ki67 is an established proliferation marker. Thus, in this study, we examined a method of Sec62/Ki67 dual staining for the detection of high-grade dysplasia and cancer in cervical liquid-based cytology specimens.
Sec62/Ki67 dual staining was performed on 100 cervical liquid-based cytology specimens. The staining results were correlated with cytological, immunocytological (p16/Ki67), colposcopic, and histological findings.
All 56 (n = 56, 100%) cases of cervical intraepithelial neoplasia grade 3 and cervical cancer (CIN3+ lesions) were positive for Sec62/Ki67 staining, while low-grade lesions and normal cells were negative. Sec62/Ki67 staining was highly sensitive and specific for the detection of CIN2+ and CIN3+ lesions (94.37%; 100% and 100%; 84.09%, respectively).
Sec62/Ki67 dual-staining immunocytochemistry is a promising cytological tool for interpreting high-grade squamous lesions in cytological specimens and for assessing the risk of progression to cancer.
KeywordsCervical cancer Cervical intraepithelial neoplasia Cytology Dual staining Immunocytochemistry Sec62
The authors would like to gratefully acknowledge the excellent work, motivation, and enthusiasm of Mrs. Barbara Linxweiler and Mrs. Alice Kunz in the establishment of our dual-staining cytology method. We also want to thank our colposcopy team, namely, Mrs. Simona Baus, Mrs. Lisa Mees, Mrs. Frederike Schlaegel, Ms. Alexandra Sehr, and Mrs. Christina Linsler, for patient recruitment and for providing high-quality LBC specimens.
FZT: project development, data collection and analysis, manuscript writing. JCR: review and editing. FB: visualization, review and editing. RMB: review and editing. IJ-B: review and editing. EFS: review and editing. BS: review and editing. ML: project development, data analysis, review and editing.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of Saarland (no: 183/17). Written informed consent was obtained from all patients prior to inclusion.
Conflict of interest
F. Z. Takacs and M. Linxweiler have a pending patent application for the Sec62/Ki67 immunocytochemical dual staining (application number: LU100824). All other authors declare no conflicts of interest.
- 7.Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R (2011) Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 121:505–509. https://doi.org/10.1016/j.ygyno.2011.02.033 CrossRefPubMedGoogle Scholar
- 12.Heselmeyer K, Macville M, Schröck E, Blegen H, Hellström AC, Shah K, Auer G, Ried T (1997) Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 19:233–240CrossRefGoogle Scholar
- 13.Hopman A, Theelen W, Hommelberg P, Kamps M, Herrington C, Morrison L, Speel E-J, Smedts F, Ramaekers F (2006) Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 210:412–419CrossRefGoogle Scholar
- 15.Wright TC, Compagno J, Romano P, Grazioli V, Verma Y, Kershnar E, Tafas T, Kilpatrick MW (2015) Amplification of the 3q chromosomal region as a specific marker in cervical cancer. Am J Obstetr Gynecol 213(51):e1–e8Google Scholar
- 22.Bochen F, Adisurya H, Wemmert S, Lerner C, Greiner M, Zimmermann R, Hasenfus A, Wagner M, Smola S, Pfuhl T, Bozzato A, Kadah BA, Schick B, Linxweiler M (2017) Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas. Oncotarget 8:4922CrossRefGoogle Scholar
- 24.Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh Joseph, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, Weir BA, Garraway LA, Tamayo P, Mesirov JP, Beroukhim R, Hahn WC (2013) Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov 3:1044–1057CrossRefGoogle Scholar
- 25.Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stöhr RF, Tornillo L, Dudek J, Stöckle M, Unteregger G, Kamradt J, Wullich B, Zimmermann R (2011) Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer 128:2284–2295. https://doi.org/10.1002/ijc.25580 CrossRefPubMedGoogle Scholar
- 26.Linxweiler M, Schorr S, Schäuble N, Jung M, Linxweiler J, Langer F, Schäfers H-J, Cavalié A, Zimmermann R, Greiner M (2013) Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer 13:574CrossRefGoogle Scholar
- 29.Oberg TN, Kipp BR, Vrana JA, Bartholet MK, Fales CJ, Garcia R, McDonald AN, Rosas BL, Henry MR, Clayton AC (2010) Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens. Diagn Cytopathol 38:564–572. https://doi.org/10.1002/dc.21251 CrossRefPubMedGoogle Scholar